Nxera Pharma Co., Ltd. (FRA:JSS)

Nxera Pharma Statistics

Total Valuation

Nxera Pharma has a market cap or net worth of EUR 424.62 million. The enterprise value is 616.74 million.

Market Cap	424.62M
Enterprise Value	616.74M

Important Dates

The next estimated earnings date is Friday, February 13, 2026.

Earnings Date	Feb 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	90.49M
Shares Outstanding	n/a
Shares Change (YoY)	+2.21%
Shares Change (QoQ)	+0.32%
Owned by Insiders (%)	10.39%
Owned by Institutions (%)	18.84%
Float	73.59M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.57
PB Ratio	1.12
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-17.43
EV / Sales	3.88
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.67

Financial Position

The company has a current ratio of 3.14, with a Debt / Equity ratio of 0.96.

Current Ratio	3.14
Quick Ratio	2.34
Debt / Equity	0.96
Debt / EBITDA	n/a
Debt / FCF	-4.52
Interest Coverage	-4.43

Financial Efficiency

Return on equity (ROE) is -9.21% and return on invested capital (ROIC) is -3.99%.

Return on Equity (ROE)	-9.21%
Return on Assets (ROA)	-3.58%
Return on Invested Capital (ROIC)	-3.99%
Return on Capital Employed (ROCE)	-6.64%
Revenue Per Employee	430,441
Profits Per Employee	-92,147
Employee Count	374
Asset Turnover	0.19
Inventory Turnover	1.47

Taxes

Income Tax	-17.64M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -30.72% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-30.72%
50-Day Moving Average	5.06
200-Day Moving Average	5.20
Relative Strength Index (RSI)	44.49
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Nxera Pharma had revenue of EUR 165.29 million and -35.38 million in losses. Loss per share was -0.39.

Revenue	165.29M
Gross Profit	117.64M
Operating Income	-48.86M
Pretax Income	-53.03M
Net Income	-35.38M
EBITDA	-24.18M
EBIT	-48.86M
Loss Per Share	-0.39

Balance Sheet

The company has 163.91 million in cash and 363.64 million in debt, giving a net cash position of -199.72 million.

Cash & Cash Equivalents	163.91M
Total Debt	363.64M
Net Cash	-199.72M
Net Cash Per Share	n/a
Equity (Book Value)	378.13M
Book Value Per Share	4.18
Working Capital	201.49M

Cash Flow

In the last 12 months, operating cash flow was -77.82 million and capital expenditures -2.61 million, giving a free cash flow of -80.44 million.

Operating Cash Flow	-77.82M
Capital Expenditures	-2.61M
Free Cash Flow	-80.44M
FCF Per Share	n/a

Margins

Gross margin is 71.17%, with operating and profit margins of -29.56% and -21.41%.

Gross Margin	71.17%
Operating Margin	-29.56%
Pretax Margin	-32.08%
Profit Margin	-21.41%
EBITDA Margin	-14.63%
EBIT Margin	-29.56%
FCF Margin	n/a

Dividends & Yields

Nxera Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.21%
Shareholder Yield	-2.21%
Earnings Yield	-8.33%
FCF Yield	-18.94%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Nxera Pharma has an Altman Z-Score of 0.85 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.85
Piotroski F-Score	1